Drugs / Damoctocog alfa pegol
last change Jun 2025 re-read 2 minutes ago

Damoctocog alfa pegol

also known as BAY94-9027 · Jivi

Protein / enzyme biologic

Developed for
hemophilia A
Investigated by
Bayer

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Jivi 2018-11-22 europa.eu

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04015492 Aug → Oct 2019 hemophilia A Bayer Completed No outcome recorded
Phase 31 trial
Phase 3 NCT05147662 Mar 2022 → Jan 2024 hemophilia A Bayer Completed No outcome recorded
Phase 42 trials
Phase 4 NCT05036278 Jul 2022 → Sep 2024 hemophilia A Bayer Completed No outcome recorded
Phase 4 NCT04085458 Sep 2019 → May 2022 hemophilia A Bayer Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as damoctocog alfa pegol “The study treatment, Jivi (also called damoctocog alfa pegol), is already available for doctors to prescribe to people with hemophilia A to treat and prevent bleeding.” NCT05036278
4

NCT05036278

NCT04085458

NCT04015492

NCT05147662

Known as BAY94-9027 “Damoctocog alfa pegol (Jivi, BAY94-9027)” NCT04085458
2

“Damoctocog-alfa-pegol (BAY94-9027, Jivi)” NCT04015492

“Damoctocog alfa pegol (Jivi, BAY94-9027)” NCT05147662

Known as Jivi “Damoctocog alfa pegol (Jivi, BAY94-9027)” NCT04085458
2

“Damoctocog-alfa-pegol (BAY94-9027, Jivi)” NCT04015492

“Damoctocog alfa pegol (Jivi, BAY94-9027)” NCT05147662

Action Restore “It works by replacing the missing FVIII, or the FVIII that does not work properly.” NCT05036278
Modality Protein / enzyme biologic “damoctocog alfa pegol and rurioctocog alfa pegol, two recombinant factor VIII (FVIII) products” PMID 32974838 Sep 2020
Route Intravenous “Both drugs are injected into a vein.” NCT04015492